New Anti-Clotting Drug Shows Promise in Hear... ( Prasugrel reduced heart risks after a...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

New Anti-Clotting Drug Shows Promise in Heart Patients

Date:11/4/2007

Prasugrel reduced heart risks after angioplasty/stenting, but raised bleeding risks when compared to Plavix

SUNDAY, Nov. 4 (HealthDay News) -- A new anti-clotting drug might one day challenge Plavix, the current standard of therapy for people who have undergone procedures to open blocked coronary arteries, a new study suggests.

But a sizable subset of the heart patients studied -- notably those who had had a prior stroke, were elderly, or had a low body weight -- faced a significantly higher risk of potentially fatal bleeding on the new drug, known as prasugrel.

Experts said it's hard to tell whether prasugrel will replace Plavix as the first medication doctors turn to after angioplasty and stenting when trying to reduce the chances of clotting and its attendant risks, which include heart attack and stroke.

"This is not an FDA-approved drug," Dr. Dan Jones, president of the American Heart Association (AHA), said Sunday during a news conference at the AHA's annual meeting in Orlando. "Many of the questions today had to do with whether this data will be sufficient for FDA approval, and I just don't know."

The trial, funded by Daiichi Sankyo Co. Ltd. and Eli Lilly & Co., will also be published in the Nov. 15 issue of the New England Journal of Medicine.

To see if the standard therapy could be improved, researchers randomly chose 13,608 patients at 707 sites in 30 countries to receive either prasugrel (60 milligrams as a one-time "loading" dose, followed by a 10-milligram maintenance dose) or Plavix (300 milligrams initially, followed by a daily 75-milligram maintenance dose) for up to 15 months following angioplasty and stenting to open blocked arteries.

"We sought to test whether a regimen that is associated with higher degrees of inhibition of platelet aggregation, meaning it inhibits the ability of platelets to clot more effectively, would reduce events in patients undergo
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine news :

1. FDA Approves New Anti-Clotting Drug
2. Aspirin surpasses Modern Anti-clotting Drugs
3. Enduring anti-clotting treatment avails heart patients
4. New Anti-Clotting Drug Less Risky For Heart Attack Patients
5. Bivalirudin, a new anti-clotting drug may be a safer option for treatment of acute coronary conditions
6. Warfarin’s Anti-clotting Property May Cause Hemorrhagic Stroke
7. Experimental treatment for Ebola Virus Shows promising results in mice
8. Gene Therapy shows promise in treating Hemophilia
9. New Prostate Cancer Vaccine Shows Promise
10. Leukemia pill shows promise against stomach cancer
11. Stent shows promise in keeping arteries open

Post Your Comments:

Related Image:

New Anti-Clotting Drug Shows Promise in Heart Patients

[0] The Flag Company, Inc.'s Recently Released “Feel Good” Light Lenses Grows Into Its Own Website [1] Winner Medical Reports Fourth Quarter and Fiscal 2009 Results [0] Patriot Scientific Corporation Announces New Director [1] Washington Regional Partners with U.S. Preventive Medicine to Bring a New Level of Preventive Health Care Services to Northwest Arkansas [1] Industry Coalition Reissues Advisory Against Use of Dietary Supplements as Swine Flu Remedy, Cure

Other Medicine News:Health News:Agito Networks Wins the 2008 VON Magazine Innovator Award for Enterprise Mobility 2 Health News:Agito Networks Wins the 2008 VON Magazine Innovator Award for Enterprise Mobility 3 Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 2 Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 3 Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 4 Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 2 Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 3 Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 4 Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 5 Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 6 Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 7 Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 2 Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 3 Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 4 Health News:Hope In Action: Policymakers and Artists Promote Youth and Latino Suicide Prevention 2 Health News:Hope In Action: Policymakers and Artists Promote Youth and Latino Suicide Prevention 3

Medivation to Present at Cowen and Company's 28th Annual Health Care Conference Agito Networks Wins the 2008 VON Magazine Innovator Award for Enterprise Mobility Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results Hope In Action: Policymakers and Artists Promote Youth and Latino Suicide Prevention

Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7 Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2 Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3 For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2 For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3 Eliminate the Blues with Color Therapy 54599 1 Eliminate the Blues with Color Therapy 54599 2 Eliminate the Blues with Color Therapy 54599 3 New biofactories produce rare healing substances in the endangered Devils claw plant 54597 1 New biofactories produce rare healing substances in the endangered Devils claw plant 54597 2 New biofactories produce rare healing substances in the endangered Devils claw plant 54597 3 Heroes of Chemistry for saving teeth clean water new high blood pressure drug 54594 1 Heroes of Chemistry for saving teeth clean water new high blood pressure drug 54594 2 Heroes of Chemistry for saving teeth clean water new high blood pressure drug 54594 3 Heroes of Chemistry for saving teeth clean water new high blood pressure drug 54594 4

[0] Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology [0] Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day [0] For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain

Other Medicine Technology:Controversial Shoulder Surgery for First-time Dislocation Proven Effective Long-Term 2 Controversial Shoulder Surgery for First-time Dislocation Proven Effective Long-Term 3 AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin 2

Controversial Shoulder Surgery for First-time Dislocation Proven Effective Long-Term AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin

Medicine Products:

Encephalitis Antibodies, IgG Electrophoresis, Protein, Serum with Reflex to Immunofixation Electrophoresis, Serum Electrolytes, Serum or Plasma Elavil (Amitriptyline/Nortriptyline)

New Anti-Clotting Drug Shows Promise in Hear...( Prasugrel reduced heart risks after a...),Health